Unknown

Dataset Information

0

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).


ABSTRACT: The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in patients with type 2 diabetes mellitus (T2DM).Adult patients with T2DM and CHD (N = 93) on a stable dose of simvastatin 20 mg with LDL-C >or= 2.6 mmol/L (100 mg/dL) and

SUBMITTER: Bardini G 

PROVIDER: S-EPMC2887787 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).

Bardini Gianluca G   Giorda Carlo B CB   Pontiroli Antonio E AE   Le Grazie Cristina C   Rotella Carlo M CM  

Cardiovascular diabetology 20100521


<h4>Background</h4>The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in patients with type 2 diabetes mellitus (T2DM).<h4>Methods</h4>Adult patients with T2DM and CHD (N = 93) on a stable dose of simvastatin 20 mg with LDL-C >or= 2.6 mmol/L (100 mg/dL) and <or= 4.1 mmol/L (160 mg/dL) were randomized to ezetimibe 10 mg plus  ...[more]

Similar Datasets

| S-EPMC3306831 | biostudies-literature
| S-EPMC4270085 | biostudies-literature
| S-EPMC7451794 | biostudies-literature
| S-EPMC3403927 | biostudies-literature
| S-EPMC5108468 | biostudies-literature
| S-EPMC3609731 | biostudies-literature
| S-EPMC6700958 | biostudies-literature
| S-EPMC2918617 | biostudies-literature
| S-EPMC4845700 | biostudies-literature
| S-EPMC5619955 | biostudies-literature